Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Clinical Pathways
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Pharmacy Benefit Managers (PBMs)
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 259 Results
The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
NPC’s commentary in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients.
Prescription Rebate Guarantees: Employer Insights
Nearly two-thirds of employer drug benefit decision makers reported having rebate agreements with a rebate guarantee for specialty drugs, according to new research from NPC published in the American…
Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Four states have given these boards authority to set drug prices. Published in Health Affairs Forefront, this primer highlights the uncertainties, challenges, and unintended consequences for patients…
The Impact of Patient Copay Accumulators and Maximizers on Out-of-Pocket Costs and Medication Persistence
Featured at #AMCP2024, this research explores the impact of Copay Accumulators and Maximizers on Patients
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance
Published in the Journal of Managed Care and Specialty Pharmacy, this study found that low-income and non-white individuals participating in commercial health plans have lower usage of specialty…
Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program
Published in JAMA Health Forum, this study examined current Medicare beneficiary access to the drugs selected for the first round of the Inflation Reduction Act’s Medicare Drug Price Negotiation…
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (DPNP) may lead to fewer subsequent indications and delay launches for small molecule drugs, according to new research from…
Guiding Practices for Patient-Centered Value Assessment (2024)
NPC has updated its Guiding Practices for Patient-Centered Value Assessment. This update of NPC's guiding practices for US value assessment will help inform the growing importance of this tool to…